| Drug ID: | Drug148 |
|---|---|
| Drug Name: | Upadacitinib |
| CID: | 58557659 |
| DrugBank ID: | DB15091 |
| Modality: | Small Molecule |
| Groups: | NULL |
| US Approved: | YES |
| Other Approved: | YES |
| Identifier: | NCT06780683, , NCT06274996, , NCT05782907, , NCT06095596, , NCT03653026, , NCT02819635, , NCT03345836, , NCT05867329 |
| Molecular Formula: | C17H19F3N6O |
| Molecular Weight: | 380.4 g/mol |
| Isomeric SMILES: | CC[C@@H]1CN(C[C@@H]1C2=CN=C3N2C4=C(NC=C4)N=C3)C(=O)NCC(F)(F)F |
| Synonyms: | Upadacitinib; ABT-494; Rinvoq; Upadacitinib anhydrous; UNII-4RA0KN46E0; 4RA0KN46E0; ABT 494; ABBV-599 COMPONENT UPADACITINIB; 1-Pyrrolidinecarboxamide, 3-ethyl-4-(3H-imidazo(1,2-a)pyrrolo(2,3-e)pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)-, (3S,4R)-; REL-(-)-(3S,4R)-3-ETHYL-4-(3H-IMIDAZO(1,2-A)PYRROLO(2,3-E)PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE |
| Phase 0: | 1 |
| Phase 1: | 6 |
| Phase 2: | 17 |
| Phase 3: | 49 |
| Phase 4: | 10 |
| Description: | NULL |
Molecular Structure
Knowledge Graph
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
|---|---|---|---|---|---|---|---|
| dt1172 | 58557659 | Upadacitinib | 3718 | JAK3 | Homo sapiens (human) | None | |
| dt1173 | 58557659 | Upadacitinib | 3718 | JAK3 | Homo sapiens (human) | Inhibitor | |
| dt1174 | 58557659 | Upadacitinib | 3716 | JAK1 | Homo sapiens (human) | Inhibition | |
| dt1175 | 58557659 | Upadacitinib | 3717 | JAK2 | Homo sapiens (human) | Inhibition | |
| dt1176 | 58557659 | Upadacitinib | 3718 | JAK3 | Homo sapiens (human) | Inhibition | |
| dt1177 | 58557659 | Upadacitinib | 7297 | TYK2 | Homo sapiens (human) | Inhibitor | |
| dt1178 | 58557659 | Upadacitinib | 1565 | CYP2D6 | Homo sapiens (human) | None | |
| dt1179 | 58557659 | Upadacitinib | 3716 | JAK1 | Homo sapiens (human) | None |
- No data available
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| NCT07442045 | Real-World Effectiveness and Safety of Upadacitinib Plus Vedolizumab vs Upadacitinib Monotherapy During Induction in Moderate-to-Severe Ulcerative Colitis | NULL | RECRUITING | Sixth Affiliated Hospital, Sun Yat-sen University | Ulcerative Colitis (UC) | DRUG: Upadacitinib|DRUG: Vedolizumab | Details |
| NCT05496348 | Study of Oral Upadacitinib to Assess Change in Disease Activity in Adult Participants With Ulcerative Colitis | NULL | RECRUITING | AbbVie | Ulcerative Colitis | None | Details |
| NCT05494606 | An Observational Study to Assess Change in Disease Activity and Adverse Events of Upadacitinib in Adult Participants With Moderate to Severe Ulcerative Colitis (UC) in Real-World Practice | NULL | ACTIVE_NOT_RECRUITING | AbbVie | Ulcerative Colitis | None | Details |
| NCT07138898 | Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty | PHASE2 | NOT_YET_RECRUITING | NYU Langone Health | Rheumatic Disease | DRUG: Methotrexate|DRUG: Sulfasalazine|DRUG: Hydr… | Details |
| NCT07073079 | A Study to Assess the Effectiveness of Second-Line Therapy of Upadacitinib and Risankizumab in Adult Participants With Crohn's Disease in a Real-World Setting | NULL | RECRUITING | AbbVie | Crohn's Disease | None | Details |
| NCT03653026 | A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Ulcerative Colitis | PHASE3 | COMPLETED | AbbVie | Ulcerative Colitis (UC) | DRUG: Placebo|DRUG: Upadacitinib | Details |
| NCT06922331 | Upadacitinib for Refractory IBD in Asian Children and Elderly: Age-Stratified Analysis | NULL | COMPLETED | Sixth Affiliated Hospital, Sun Yat-sen University | Crohn's Disease (CD)|Ulcerative Colitis (UC)|… | DRUG: Upadacitinib | Details |
| NCT03345849 | A Study of the Efficacy and Safety of Upadacitinib in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional and/or Biologic Therapies | PHASE3 | COMPLETED | AbbVie | Crohn's Disease | DRUG: Upadacitinib|DRUG: Placebo for Upadacitinib | Details |
| NCT03345836 | A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy | PHASE3 | COMPLETED | AbbVie | Crohn's Disease | DRUG: Matching Placebo for Upadacitinib|DRUG: Upa… | Details |
| NCT03345823 | A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433 | PHASE3 | ACTIVE_NOT_RECRUITING | AbbVie | Crohn's Disease | DRUG: Upadacitinib|DRUG: Placebo for Upadacitinib | Details |
| NCT03006068 | A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) | PHASE3 | ACTIVE_NOT_RECRUITING | AbbVie | Ulcerative Colitis (UC) | DRUG: Upadacitinib (ABT-494)|DRUG: Placebo | Details |
| NCT06838845 | An Observational Study to Evaluate Effectiveness and Safety of Upadacitinib in Chinese Adult Participants With Moderate to Severely Active Ulcerative Colitis (UC) | NULL | RECRUITING | AbbVie | Ulcerative Colitis | None | Details |
| NCT02819635 | A Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (UC) | PHASE2|PHASE3 | COMPLETED | AbbVie | Ulcerative Colitis (UC) | DRUG: Placebo|DRUG: Upadacitinib | Details |
| NCT02782663 | A Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Participants With Crohn's Disease | PHASE2 | COMPLETED | AbbVie | Crohn's Disease (CD) | DRUG: ABT-494 | Details |
| NCT06780683 | Efficacy and Safety of Upadacitinib in Inflammatory Bowel Disease | NULL | RECRUITING | Xiang Gao | Inflammatory Bowel Disease|Crohn's Disease|Ulcera… | DRUG: Upadacitinib | Details |
| NCT06660693 | Comparison of Medical RESCUE Strategies for Patients With Steroid-refractory Acute Severe Ulcerative Colitis | PHASE3 | RECRUITING | McMaster University | Colitis, Ulcerative | DRUG: Upadacitinib Oral Product | Details |
| NCT06581042 | Study to Assess Treatment Patterns and Outcomes With Upadacitinib in Adult Participants With Inflammatory Bowel Disease in Belgium | NULL | RECRUITING | AbbVie | Ulcerative Colitis|Crohn's Disease | None | Details |
| NCT06573944 | IUS Predicts Upadacitinib Efficacy in Patients With Moderate to Severe Crohn's Disease：a Prospective Study | NULL | UNKNOWN | The Third Xiangya Hospital of Central South University | Crohn's Disease|Upadacitinib|Intestinal Ultrasoun… | None | Details |
| NCT06520397 | Efficacy and Safety of Dual-targeted Therapy With Upadacitinib and Ustekinumab Versus Intensified Ustekinumab Therapy in Crohn's Disease | PHASE4 | RECRUITING | Sixth Affiliated Hospital, Sun Yat-sen University | Crohn Disease | DRUG: Ustekinumab and Upadacitinib|DRUG: Ustekinu… | Details |
| NCT06498167 | Active Pharmacovigilance Study of the Medicine Rinvoq™ (Upadacitinib) | NULL | RECRUITING | Universidade do Porto | Inflammatory Disease|Drug Side Effect|Drug Use|Ad… | DRUG: Upadacitinib | Details |
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| No data available | ||||||
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| S07 | Blockade of cytokine | Cytokine signalling | apremilast; roflumilast; filgotinib; tofacitinib; ABT494; ABT-874; ustekinumab; isankizumab; LY-2525623; AMG139; MEDI2079; guselkumab | Various T-cell subsets, their differentiation pathways and … | Details |
Upadacitinib in end stage renal disease: A case of acute severe ulcerative coli…
PMID: 38162859
Year: 2023
Relationship Type:
Association
Score: 6.5
Recent data, indicating that inflammatory bowel disease (IBD) may be a risk factor for future chronic kidney disease, highlight the need to study the…
Single-center Experience With Upadacitinib for Adolescents With Refractory Infl…
PMID: 38134405
Year: 2024
Relationship Type:
Treatment
Score: 6.5
BACKGROUND: Upadacitinib (UPA) is a novel selective JAK inhibitor approved for adults with ulcerative colitis (UC) and with positive phase 3 data for…
Dual-Targeted Therapy with Upadacitinib and Ustekinumab in Medically Complex Cr…
PMID: 38112840
Year: 2024
Relationship Type:
Treatment
Score: 6.5
BACKGROUND AND AIMS: Ongoing efforts to break the therapeutic ceiling in inflammatory bowel disease include combination therapy approaches. Dual-targ…
Efficacy and safety of upadacitinib for 16-week extended induction and 52-week …
PMID: 38010661
Year: 2024
Relationship Type:
Treatment
Score: 6.5
BACKGROUND: Upadacitinib is an oral, selective Janus kinase inhibitor. AIM: To assess the efficacy and safety of upadacitinib in patients with modera…
Efficacy of Upadacitinib As a Second-line JAK Inhibitor in Ulcerative Colitis: …
PMID: 38008454
Year: 2024
Relationship Type:
Treatment
Score: 6.5
Upadacitinib, a recently approved Janus kinase (JAK) inhibitor specific for JAK1, may be a promising candidate in patients with ulcerative colitis (U…
Effectiveness and safety of upadacitinib for inflammatory bowel disease: A syst…
PMID: 37977068
Year: 2024
Relationship Type:
Treatment
Score: 6.5
BACKGROUND: Upadacitinib, a novel and selective inhibitor of Janus kinase 1, has demonstrated promising efficacy in managing inflammatory bowel disea…
Upadacitinib as a Rescue Therapy in Acute Severe Ulcerative Colitis: A Case Rep…
PMID: 37926993
Year: 2023
Relationship Type:
Treatment
Score: 6.5
BACKGROUND Ulcerative colitis (UC) is a chronic immune-mediated disease of the colon. The mainstay of treatment to achieve and maintain remission is …
In moderate-to-severe Crohn disease, upadacitinib increased clinical remission …
PMID: 37665995
Year: 2023
Relationship Type:
Treatment
Score: 6.5
Loftus EV Jr, Panes J, Lacerda AP, et al. Upadacitinib induction and maintenance therapy for Crohn's disease. N Engl J Med. 2023;388:1966-1980. 37224…
Upadacitinib Salvage Therapy for Infliximab-Experienced Patients with Acute Sev…
PMID: 37422724
Year: 2023
Relationship Type:
Treatment
Score: 6.5
BACKGROUND AND AIMS: Acute severe ulcerative colitis [ASUC] is a medical emergency treated with intravenous steroids followed by infliximab or cyclos…
Upadacitinib Induction and Maintenance Therapy for Crohn's Disease
PMID: 37224198
Year: 2023
Relationship Type:
Treatment
Score: 6.5
BACKGROUND: Upadacitinib, an oral selective Janus kinase (JAK) inhibitor, is under investigation for the treatment of Crohn's disease. METHODS: In tw…
A case of nocardiosis in a patient with ulcerative colitis on chronic corticost…
PMID: 37207089
Year: 2023
Relationship Type:
Treatment
Score: 6.5
KEY CLINICAL MESSAGE: Immunosuppression, malnutrition, and underlying infection can unmask obscure infections which can be challenging to identify. E…
The role of upadacitinib in the treatment of ulcerative colitis
PMID: 37129377
Year: 2023
Relationship Type:
Treatment
Score: 6.5
The JAK signaling pathway plays a major role in the immunopathology of autoimmune diseases, including inflammatory bowel disease. JAK enzymes provide…
Atopic Dermatitis and Ulcerative Colitis Successfully Treated with Upadacitinib
PMID: 36984542
Year: 2023
Relationship Type:
Treatment
Score: 6.5
Background and Objectives: JAK inhibitors entered current clinical practice as treatment for several immune-related diseases and, recently, for atopi…
Successful treatment of concomitant alopecia universalis and Crohn's disease wi…
PMID: 36968986
Year: 2023
Relationship Type:
Treatment
Score: 6.5
Alopecia areata is a non-scarring, autoimmune hair loss disorder that is associated with inflammatory bowel disease. Alopecia areata and inflammatory…
Update on the role of upadacitinib in the treatment of adults with moderately t…
PMID: 36923487
Year: 2023
Relationship Type:
Treatment
Score: 6.5
With further knowledge of the pathogenesis of inflammatory bowel disease, small oral molecules have become available, including the Janus kinase (JAK…
Upadacitinib Is Effective and Safe in Both Ulcerative Colitis and Crohn's Disea…
PMID: 36898598
Year: 2023
Relationship Type:
Treatment
Score: 6.5
BACKGROUND & AIMS: Upadacitinib is a novel selective Janus kinase 1 inhibitor that has shown efficacy in the treatment of moderate to severe ulcerati…
Upadacitinib Induction and Maintenance Therapy Improves Abdominal Pain, Bowel U…
PMID: 36790041
Year: 2023
Relationship Type:
Treatment
Score: 6.5
BACKGROUND: This post hoc analysis of a large, phase 3 program evaluated the effects of upadacitinib on fatigue, bowel urgency, and abdominal pain in…
Medically Refractory Lymphocytic Colitis Successfully Treated With Upadacitinib
PMID: 36788789
Year: 2023
Relationship Type:
Association
Score: 6.5
Lymphocytic colitis is a microscopic colitis characterized endoscopically by nearly normal-appearing colonic mucosa and histology demonstrating intra…
A critical review of upadacitinib for the treatment of adults with moderately t…
PMID: 36681073
Year: 2023
Relationship Type:
Treatment
Score: 6.5
INTRODUCTION: Upadacitinib is a selective janus kinase 1 inhibitor. In March 2022, upadacitinib was approved by the US Food and Drug Administration f…
Induction and Maintenance Treatment With Upadacitinib Improves Health-Related Q…
PMID: 36645051
Year: 2023
Relationship Type:
Treatment
Score: 6.5
BACKGROUND: We evaluated the health-related quality of life (HRQoL) benefits of upadacitinib (UPA) induction and maintenance treatment in a phase 3 s…